通过组织学分析对原发性皮肤黑色素瘤的前哨淋巴结风险进行预后预测,可能重新定义前哨淋巴结活检的必要性
本综述探讨基因表达谱(GEP)和免疫组化(IHC)等分子检测平台预测皮肤黑色素瘤前哨淋巴结(SLN)预后的作用,并与传统分期评估比较。目前多种平台(DecisionDx、Merlin Assay、MelaGenix GEP、Immunoprint)正在验证中,但因样本量有限、缺乏前瞻性验证及与临床病理变量相关性有限等方法学缺陷,广泛临床应用尚难实现。
要点
- GEP和IHC平台有潜力对前哨淋巴结阳性(SLNP)风险进行分层,但多数存在显著方法学缺陷。
- 不同GEP或IHC检测所鉴定的基因和蛋白重叠极少,即使考虑最明确的黑色素瘤突变。
- Merlin Assay正在进行的前瞻性试验若成功,可能安全减少前哨淋巴结活检(SLNB)的必要性。
核心结论
- 多种组织分子检测平台有潜力对SLNP风险进行分层,但多数存在显著方法学缺陷,包括样本量有限、缺乏前瞻性验证及与已确立的临床病理变量相关性有限。
- 不同GEP或IHC检测所鉴定的基因和蛋白重叠极少,即使考虑最明确的黑色素瘤突变。
- Merlin Assay正在进行的前瞻性试验若成功,可能安全减少SLNB的必要性。
- MelaGenix GEP和Immunoprint检测可能有助于识别高风险I-II期黑色素瘤患者并潜在指导其辅助治疗选择,从而可能减少SLNB的需求。
- 由于研究设计多样,GEP或IHC检测之间难以有效比较,且迄今没有研究直接比较这些各自GEP或IHC检测的临床效用。
研究设计与样本
- 综述,检索范围未在原文中明确报告。
主要发现
- 辅助黑色素瘤治疗的进展降低了SLNB的必要性,同时强调准确识别可能从额外抗肿瘤干预中获益的高风险I期和II期黑色素瘤患者的重要性。
- GEP或IHC检测的临床应用日益增多,DecisionDx、Merlin Assay(CP-GEP)、MelaGenix GEP和Immunoprint等平台正在投入使用。
- 目前正在进行广泛验证研究,以将常规分子检测纳入临床实践;但由于显著的方法学限制,基于组织的分子检测的广泛临床采用目前仍难以实现。
- GEP和IHC检测之间共享的遗传和蛋白标志物及其与黑色素瘤生物学的相关性未在原文中报告具体数值。
关键数值与推荐
- 原文未报告具体阈值、剂量或推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数组织分子检测平台存在显著方法学缺陷,包括样本量有限、缺乏前瞻性验证及与已确立的临床病理变量相关性有限。
- 不同GEP或IHC检测所鉴定的基因和蛋白重叠极少,即使考虑最明确的黑色素瘤突变。
- 由于研究设计多样,GEP或IHC检测之间难以有效比较,且迄今没有研究直接比较这些各自GEP或IHC检测的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF REVIEW: The role of Sentinel Lymph Node Biopsy (SLNB) is pivotal in the contemporary staging of cutaneous melanoma. In this review, we examine advanced molecular testing platforms like gene expression profiling (GEP) and immunohistochemistry (IHC) as tools for predicting the prognosis of sentinel lymph nodes. We compare these innovative approaches with traditional staging assessments. Additionally, we delve into the shared genetic and protein markers between GEP and IHC tests and their relevance to melanoma biology, exploring their prognostic and predictive characteristics. Finally, we assess alternative methods to potentially obviate the need for SLNB altogether. RECENT FINDINGS: Progress in adjuvant melanoma therapy has diminished the necessity of Sentinel Lymph Node Biopsy (SLNB) while underscoring the importance of accurately identifying high-risk stage I and II melanoma patients who may benefit from additional anti-tumor interventions. The clinical application of testing through gene expression profiling (GEP) or immunohistochemistry (IHC) is gaining traction, with platforms such as DecisionDx, Merlin Assay (CP-GEP), MelaGenix GEP, and Immunoprint coming into play. Currently, extensive validation studies are in progress to incorporate routine molecular testing into clinical practice. However, due to significant methodological limitations, widespread clinical adoption of tissue-based molecular testing remains elusive at present. SUMMARY: While various tissue-based molecular testing platforms have the potential to stratify the risk of sentinel lymph node positivity (SLNP), most suffer from significant methodological deficiencies, including limited sample size, lack of prospective validation, and limited correlation with established clinicopathological variables. Furthermore, the genes and proteins identified by individual gene expression profiling (GEP) or immunohistochemistry (IHC) tests exhibit minimal overlap, even when considering the most well-established melanoma mutations. However, there is hope that the ongoing prospective trial for the Merlin Assay may safely reduce the necessity for SLNB procedures if successful. Additionally, the MelaGenix GEP and Immunoprint tests could prove valuable in identifying high-risk stage I-II melanoma patients and potentially guiding their selection for adjuvant therapy, thus potentially reducing the need for SLNB. Due to the diverse study designs employed, effective comparisons between GEP or IHC tests are challenging, and to date, there is no study directly comparing the clinical utility of these respective GEP or IHC tests.
引用
- Kött J, Zimmermann N, Zell T, et al. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy. Eur J Cancer. 2024. PMID: 38518535. doi:10.1016/j.ejca.2024.113989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。